Sunrise, FL (PRWEB) November 05, 2013
Bioheart Inc., a biotech company focused on the discovery, development and commercialization of autologous cell therapies to treat cardiovascular disease, has announced an agreement with Global Stem Cells Group of Miami to provide Bioheart therapies and products to its worldwide network of physicians and qualified patients.
The agreement between the two companies also provides an opportunity for Global Stem Cells Group to expand the network by training additional physicians in Bioheart's regenerative medicine techniques while contributing to the development and commercialization of Bioheart's regenerative medicine products.
"Combining the large network of physicians at Global Stem Cells Group with currently available Bioheart therapies and products will help strengthen and broaden our program," says Mike Tomas, CEO of Bioheart, Inc. "We are looking forward to working with GSCG to expand our therapies globally and offer new therapies to patients who suffer from debilitating conditions."
Global Stem Cells Group, a biotech company specializing in adult stem cell research, therapies and products, is comprised of six cutting-edge stem cell treatment companies each with a distinct mission based on research and proven technology.
The Global Stem Cells Group offers a sophisticated global network of physicians to train other physicians in these innovative cellular therapies and techniques, and to provide them to patients from all corners of the world.
"We're very pleased to be working with Bioheart to expand their therapies globally," says Global Stem Cells Group Founder and COO Ricardo de Cubas. "Our companies are both focused on delivering cellular therapies to patients everywhere who suffer from debilitating medical conditions and disease, and that makes this collaboration a natural one."
About Bioheart, Inc.
Founded in 1999, Bioheart, Inc. is a leader in the cardiovascular sector of the cell technology industry, delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheartís goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and (subject to regulatory approval) commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. The companyís leading product, MyoCell, is a clinical, muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit the Bioheart website, Bioheart Facebook page, or Bioheart Twitter page.
About the Global Stem Cells Group;
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groupís corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGís six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
To learn more about Global Stem Cells Group, Inc., and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
Read the full story at http://www.prweb.com/releases/globalstemcellsgroup/BioheartInc/prweb11298034.htm